Pfizer announced this morning that it has initiated the next phase of a clinical trial to evaluate the safety and efficacy of its COVID-19 antiviral pill, Paxlovid, in children ages 6 to 17.

The Phase 2/3 trial is an open-label, multi-center, single-arm study in approximately 140 pediatric participants under 18 years of age.

In December, the Food and Drug Administration authorized Paxlovid to treat COVID-19 in high-risk individuals 12 and older.

The upcoming trials will test the drug at different doses for children as young as 6 years old who test positive for COVID-19 and are not hospitalized, but are also at risk of developing severe disease.